Uniting Biotech & Pharma Experts to Exchange Insights on Oligonucleotide Analytical
Development & CMC

Despite milestone progress, such as Avidity securing breakthrough designation for their oligo conjugate, significant challenges persist across the oligo landscape in impurity profiling, drug characterisation, efficient scale-up, and regulatory alignment.

80+ industry experts from analytical development, process development, CMC, analytical chemistry, and quality control have gathered at the 4th Oligonucleotide Analytical Development & CMC Summit to collaborate, network and learn cutting-edge strategies that are tackling the unique challenges in oligo analytical development and CMC scale-up.

Actionable insight were gained from case studies, presentations and deep dive discussions from Sarepta, Ionis, Biogen, Novo Nordisk, GSK, Wave Life Science, Denali, PepGen, Avidity, Alnylam and more, to advance and reshape the future of oligonucleotide drug development.